Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

bluebird bio LLC

This article was originally published in Start Up

Executive Summary

bluebird bio LLC has taken in $65 million in venture capital over the past year, thanks to encouraging studies with two different kinds of lentiviral vectors that transfer new copies of genes into patients' own stem cells. Given that vectors have different properties - one integrates into the DNA coding region, the other does not - the company might eventually be able to mix and match therapeutic gene "fillings" to vectors as needed. The start-up is ready to start commercializing gene therapies for serious genetic disorders, starting with ALD and beta-thalassemia. .
Advertisement

Related Content

Bluebird’s Share Price Skyrocketing On Beta Thalassemia Optimism
Bluebird’s Improved Vector Yields Promising Early Phase II Data In Beta Thalassemia
Edimer Pharmaceuticals Inc.
Start-Up Previews (05/2011)
Afraxis Inc.
Rare Disease Research: Where Compassion Meets Commerce
Ultragenyx Pharmaceutical LLC
Rare Disease Research: Where Compassion Meets Commerce
Start-Up Previews (05/2011)

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel